PDCD1 and colorectal carcinoma: This is being evaluated in an ongoing pilot study that combines 5-azacitidine (DNMT inhibitor) or romidepsin (HDAC inhibitor) or both with the PD-1 inhibitor pembrolizumab in MMR-proficient advanced CRC (NCT02512172).